See more : Washington Prime Group Inc. (WPG) Income Statement Analysis – Financial Results
Complete financial analysis of Gossamer Bio, Inc. (GOSS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gossamer Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Ju Teng International Holdings Limited (9136.TW) Income Statement Analysis – Financial Results
- Valeura Energy Inc. (VLU.L) Income Statement Analysis – Financial Results
- Ginkgo Bioworks Holdings, Inc. WT (DNA-WT) Income Statement Analysis – Financial Results
- Marico Limited (MARICO.NS) Income Statement Analysis – Financial Results
- Kaushalya Infrastructure Development Corporation Limited (KAUSHALYA.BO) Income Statement Analysis – Financial Results
Gossamer Bio, Inc. (GOSS)
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.39M | 4.43M | 5.17M | 4.27M | 3.09M | 297.00K | 0.00 | 0.00 |
| Gross Profit | -4.39M | -4.43M | -5.17M | -4.27M | -3.09M | -297.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 145.30M | 170.92M | 170.27M | 160.85M | 143.40M | 55.28M | 891.00K | 0.00 |
| General & Administrative | 38.46M | 47.61M | 45.78M | 49.73M | 39.14M | 44.05M | 262.00K | 83.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 38.46M | 47.61M | 45.78M | 49.73M | 39.14M | 44.05M | 262.00K | 83.00K |
| Other Expenses | 0.00 | 1.51M | 799.00K | -174.00K | 5.83M | 316.00K | 0.00 | 0.00 |
| Operating Expenses | 183.76M | 218.53M | 216.05M | 210.58M | 182.54M | 99.33M | 1.15M | 83.00K |
| Cost & Expenses | 183.76M | 218.53M | 216.05M | 210.58M | 182.54M | 99.33M | 1.15M | 83.00K |
| Interest Income | 2.00M | 1.58M | 761.00K | 3.44M | 3.63K | 1.72M | 0.00 | 0.00 |
| Interest Expense | 13.51M | 13.88M | 19.44M | 12.67M | 0.00 | 12.00K | 118.00K | 0.00 |
| Depreciation & Amortization | 1.61M | 4.43M | 5.17M | 4.27M | 3.09M | 297.00K | 1.15M | 83.00K |
| EBITDA | -172.15M | -211.07M | -209.32M | -233.96M | -186.14M | -148.99M | -6.65M | -83.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -183.76M | -218.59M | -216.12M | -233.96M | -186.14M | -148.99M | -6.65M | -83.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.94M | -10.79M | -17.88M | -9.40M | 5.83M | 2.02M | -118.00K | 0.00 |
| Income Before Tax | -179.82M | -229.38M | -234.00M | -243.36M | -180.31M | -146.97M | -6.77M | -83.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 10.85M | 15.07M | 8.22M | 511.00K | 2.04M | -5.38M | -83.00K |
| Net Income | -179.82M | -240.23M | -249.08M | -251.58M | -180.82M | -146.97M | -6.77M | -83.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.18 | -2.84 | -3.33 | -3.67 | -3.30 | -2.43 | -0.27 | 0.00 |
| EPS Diluted | -1.18 | -2.84 | -3.33 | -3.67 | -3.30 | -2.43 | -0.27 | 0.00 |
| Weighted Avg Shares Out | 152.62M | 84.57M | 74.84M | 68.51M | 54.74M | 60.40M | 24.83M | 24.83M |
| Weighted Avg Shares Out (Dil) | 152.62M | 84.57M | 74.84M | 68.51M | 54.74M | 60.40M | 24.83M | 24.83M |
Gossamer Bio to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 10, 2020
Gossamer Bio Announces GB1275 Data Presentations at 2020 Society for Immunotherapy of Cancer Annual Meeting
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
Voloridge Investment Management LLC Takes Position in Gossamer Bio Inc (NASDAQ:GOSS)
Insider Buying: Gossamer Bio Inc (NASDAQ:GOSS) CFO Purchases $25,920.00 in Stock
Gossamer Bio (NASDAQ:GOSS) Upgraded to Hold at Zacks Investment Research
Zacks Investment Research Downgrades Gossamer Bio (NASDAQ:GOSS) to Sell
Gossamer Bio Inc (NASDAQ:GOSS) Shares Acquired by Alliancebernstein L.P.
Russell Investments Group Ltd. Lowers Holdings in Gossamer Bio Inc (NASDAQ:GOSS)
FINAL DEADLINE: ROSEN, A TRUSTED AND RANKED FIRM, Encourages Gossamer Bio, Inc. Investors with Losses to Contact Firm Before Important June 2 Deadline in Securities Class Action- GOSS
Source: https://incomestatements.info
Category: Stock Reports